Compare ResMed Inc. (RMD) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wendys Co — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Wendys Co trades at $6.24 (market cap $1.19B). The key difference: ResMed Inc. is far larger — about 26.8× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Wendys Co for 77 Days on average.
| RMD | WEN | |
|---|---|---|
Market Cap | $31.89B | $1.19B |
Volume | 618,314 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $277.88 | $9.33 |
52-Week Low | $182.82 | $6.10 |
Typical Hold Time | 51 Days | 77 Days |
Enterprise Value | $31.24B | $4.92B |
Dividend Yield | 1.16% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Wendy's stock trades at $6.23, up 1.96% today, but remains under significant pressure with a bearish technical outlook. The company faces declining same-store sales, a major franchisee bankruptcy, and net income margin compression from 7.58% in 2025 to 5.72% projected for 2026. Despite beating earnings expectations in recent quarters, valuation metrics appear attractive with P/E of 9.45 and P/S of 0.54, though high debt levels and competitive pressures persist.
The investment case hinges on new CEO Bob Wright's turnaround execution against substantial headwinds. While the stock trades at a discount to analyst consensus target of $7.58, near-term risks from franchisee instability and market share losses to burger chain competitors outweigh valuation appeal. Recovery depends on reversing sales trends and managing $2.66 billion in long-term debt effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
